Merck (MRK) Net Income - Minority (2009 - 2012)
Merck (MRK) reported Net Income - Minority of -$2.4 billion for Q4 2012, down 0.7% year-over-year from -$2.5 billion in Q1 2012, and down 0.7% on a QoQ basis from -$2.4 billion in Q4 2011.
Merck (MRK) has 4 years of Net Income - Minority data on file, last reported at -$2.4 billion in Q4 2012.
- Quarterly Net Income - Minority fell 0.7% year-over-year to -$2.4 billion in Q4 2012, while the trailing twelve-month figure through Dec 2012 was -$2.4 billion (down 0.7% YoY) and the FY2012 annual result came in at -$2.4 billion, down 0.7% from the prior year.
- Net Income - Minority declined to -$2.4 billion in Q4 2012 per MRK's latest filing, from -$2.4 billion in the prior quarter.
- Across five years, Net Income - Minority topped out at -$2.4 billion in Q4 2011 and bottomed at -$2.5 billion in Q1 2010.
- The 4-year median for Net Income - Minority is -$2.4 billion (2010), against an average of -$2.4 billion.
- The widest annual swing landed in 2011, when Net Income - Minority rose 0.41%; it then declined 0.7% in 2012.
- Tracing MRK's Net Income - Minority over 4 years: stood at -$2.4 billion in 2009, then decreased by 0.08% to -$2.4 billion in 2010, then increased by 0.12% to -$2.4 billion in 2011, then slipped by 0.7% to -$2.4 billion in 2012.
- Per Business Quant, the three latest MRK Net Income - Minority figures stand at -$2.4 billion (Q4 2012), -$2.4 billion (Q4 2011), and -$2.5 billion (Q1 2011).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income - Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | - |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | - |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | - |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | - |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | - |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2012 | -2.44 Bn |
| Dec 31, 2011 | -2.43 Bn |
| Mar 31, 2011 | -2.46 Bn |
| Dec 31, 2010 | -2.43 Bn |
| Sep 30, 2010 | -2.46 Bn |
| Jun 30, 2010 | -2.43 Bn |
| Mar 31, 2010 | -2.47 Bn |
| Dec 31, 2009 | -2.43 Bn |